Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
Animals
Azithromycin
/ pharmacology
Betacoronavirus
/ drug effects
COVID-19
Chlorocebus aethiops
Coronavirus Infections
/ drug therapy
Cytokines
/ blood
Disease Models, Animal
Female
Humans
Hydroxychloroquine
/ pharmacokinetics
In Vitro Techniques
Kinetics
Macaca fascicularis
Male
Pandemics
Pneumonia, Viral
/ drug therapy
Pre-Exposure Prophylaxis
Respiratory Mucosa
/ cytology
SARS-CoV-2
Time Factors
Treatment Failure
Vero Cells
Viral Load
/ drug effects
COVID-19 Drug Treatment
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
30
04
2020
accepted:
10
07
2020
pubmed:
23
7
2020
medline:
6
10
2020
entrez:
23
7
2020
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic and no antiviral drug or vaccine is yet available for the treatment of this disease
Identifiants
pubmed: 32698191
doi: 10.1038/s41586-020-2558-4
pii: 10.1038/s41586-020-2558-4
doi:
Substances chimiques
Cytokines
0
Hydroxychloroquine
4QWG6N8QKH
Azithromycin
83905-01-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
584-587Références
He, X. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 26, 672–675 (2020).
doi: 10.1038/s41591-020-0869-5
Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
doi: 10.1016/S0140-6736(20)30183-5
Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620–2629 (2020).
doi: 10.1172/JCI137244
Touret, F. & de Lamballerie, X. Of chloroquine and COVID-19. Antiviral Res. 177, 104762 (2020).
doi: 10.1016/j.antiviral.2020.104762
Touret, F. et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci. Rep. 10, 13093 (2020).
doi: 10.1038/s41598-020-70143-6
Gautret, P. et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med. Infect. Dis. 34, 101663 (2020).
doi: 10.1016/j.tmaid.2020.101663
Magagnoli, J. et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. Med 1, 1–14 (2020).
Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199–1207 (2020).
doi: 10.1056/NEJMoa2001316
Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020).
doi: 10.1038/s41422-020-0282-0
Liu, J. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 6, 16 (2020).
doi: 10.1038/s41421-020-0156-0
Ponticelli, C. & Moroni, G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin. Drug Saf. 16, 411–419 (2017).
doi: 10.1080/14740338.2017.1269168
Savarino, A., Di Trani, L., Donatelli, I., Cauda, R. & Cassone, A. New insights into the antiviral effects of chloroquine. Lancet Infect. Dis. 6, 67–69 (2006).
doi: 10.1016/S1473-3099(06)70361-9
Rainsford, K. D., Parke, A. L., Clifford-Rashotte, M. & Kean, W. F. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23, 231–269 (2015).
doi: 10.1007/s10787-015-0239-y
Schrezenmeier, E. & Dörner, T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol. 16, 155–166 (2020).
doi: 10.1038/s41584-020-0372-x
Monzavi, S. M. et al. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers. Inflammopharmacology 26, 1175–1182 (2018).
doi: 10.1007/s10787-018-0512-y
Fanouriakis, A. et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann. Rheum. Dis. 79, 713–723 (2020).
pubmed: 32220834
Zhang, B. et al. Macrolide derivatives reduce proinflammatory macrophage activation and macrophage-mediated neurotoxicity. CNS Neurosci. Ther. 25, 591–600 (2019).
doi: 10.1111/cns.13092
Rockx, B. et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368, 1012–1015 (2020).
doi: 10.1126/science.abb7314
Williamson, B. N. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature https://doi.org/10.1038/s41586-020-2423-5 (2020).
Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124 (2020).
doi: 10.1038/s41586-020-2381-y
Yao, X. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 71, 732–739 (2020).
doi: 10.1093/cid/ciaa237
Nicolas de Lamballerie, C. et al. Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia. Sci. Rep. 9, 11493 (2019).
doi: 10.1038/s41598-019-48013-7
Pizzorno, A. et al. Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. Cell. Rep. Med 1, 100059 (2020).
doi: 10.1016/j.xcrm.2020.100059
Pan, F. et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology 295, 715–721 (2020).
doi: 10.1148/radiol.2020200370
Shi, H. et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect. Dis. 20, 425–434 (2020).
doi: 10.1016/S1473-3099(20)30086-4
Tett, S. E., Cutler, D. J., Day, R. O. & Brown, K. F. A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br. J. Clin. Pharmacol. 26, 303–313 (1988).
doi: 10.1111/j.1365-2125.1988.tb05281.x
Liu, Y. et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect. Dis. 20, 656–657 (2020).
doi: 10.1016/S1473-3099(20)30232-2
Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513 (2020).
doi: 10.1016/S0140-6736(20)30211-7
Roques, P. et al. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses 10, 268 (2018).
doi: 10.3390/v10050268
Chhonker, Y. S., Sleightholm, R. L., Li, J., Oupický, D. & Murry, D. J. Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: an application for pharmacokinetic studies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1072, 320–327 (2018).
doi: 10.1016/j.jchromb.2017.11.026
Lescure, F. X. et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect. Dis. 20, 697–706 (2020).
doi: 10.1016/S1473-3099(20)30200-0